Table 1.
a. Univariate models for overall survival (OS), relapse free survival (RFS) and/or survival after relapse (SAR) by ΔPC1.EMT score on PETACC3 Stage II&III and Stage III patients | |||
---|---|---|---|
Covariates | HR (95% CI) | p | n |
OS for Stage II and III | 1.56 (1.32–1.84) | 1.16e-07 | 752 |
| |||
OS for Stage III | 1.69 (1.42–2.03) | 8.22e-09 | 644 |
| |||
RFS for Stage II and III | 1.47 (1.28–1.69) | 8.98e-08 | 752 |
| |||
RFS for Stage III | 1.55 (1.33–1.81) | 3.99e-08 | 644 |
| |||
SAR for Stage II and III | 1.20 (1.02–1.42) | 3.11e-02 | 291 |
| |||
SAR for Stage III | 1.26 (1.04–1.51) | 1.54e-02 | 241 |
b. Univariate models for OS by ΔPC1.EMT, PC1 and EMT scores as well as other clinic-pathological and molecular variables on PETACC3 Stage III patients (n=644) | ||
---|---|---|
Covariates | HR (95% CI) | p |
ΔPC1.EMT | 1.69 (1.42–2.03) | 8.22e-09 |
PC1 | 1.41 (1.20–1.67) | 5.13e-05 |
EMT | 1.28 (1.07–1.53) | 8.21e-03 |
MSI (MSS vs. MSI-H) | 1.49 (0.81–2.75) | 2.00e-01 |
BRAF (wt vs. mut) | 0.57 (0.34–0.95) | 3.04e-02 |
site (right vs. left) | 1.42 (1.06–1.91) | 1.84e-02 |
T stage (T1,2 vs. T3) | 0.36 (0.16–0.82) | 1.47e-02 |
T stage (T4 vs. T3) | 2.03 (1.45–2.86) | 4.09e-05 |
grade (G-3,4 vs. G-1,2) | 1.89 (1.26–2.82) | 2.07e-03 |
SMAD4 (Any Loss vs. No Loss) (45) | 1.57 (1.13–2.16) | 6.75e-03 |
KRAS (mut vs. wt) | 1.49 (1.10–2.01) | 9.93e-03 |
BRAF.score (23) | 1.34 (1.20–1.50) | 1.84e-07 |
Age | 1.09 (0.94–1.25) | 2.49e-01 |
LN (No. of lymph nodes) | 0.81 (0.68–0.97) | 1.95e-02 |
c. Multivariate models for OS including PC1 and EMT scores as well as other clinic-pathological and molecular variables on PETACC3_Stage III patients (n=644) | ||
---|---|---|
Covariates | HR (95% CI) | p |
PC1 | 3.22 (1.82–5.7) | 5.62e-005 |
EMT | 0.37 (0.2–0.67) | 1.14e-003 |
Age | 1.08 (0.93–1.25) | 3.14e-001 |
T stage (T1,2 vs T3) | 0.48 (0.21–1.11) | 8.65e-002 |
T stage (T4 vs T3) | 1.96 (1.39–2.77) | 1.32e-004 |
N stage (N2 vs N1) | 2.11 (1.57–2.85) | 9.50e-007 |
LN (No. of lymph nodes) | 0.73 (0.6–0.88) | 9.13e-004 |
site (right vs left) | 1.75 (1.27–2.4) | 5.75e-004 |
MSI (MSS vs MSI-H) | 1.92 (1–3.67) | 4.96e-002 |
BRAF (wt vs mut) | 0.87 (0.5–1.52) | 6.34e-001 |
d. Multivariate models for OS including ΔPC1.EMT or PC1or EMT scores as well as other clinic-pathological and molecular variables on PETACC3_Stage III patients (n=644) | ||||||
---|---|---|---|---|---|---|
ΔPC1.EMT | PC1 | EMT | ||||
Covariates | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p |
Scores | 1.50 (1.25–1.81) | 1.61e-05 | 1.32 (1.11–1.58) | 2.12e-03 | 1.21 (1.00–1.46) | 4.97e-02 |
Age | 1.04 (0.89–1.20) | 6.37e-01 | 1.04 (0.90–1.21) | 5.95e-01 | 1.03 (0.89–1.20) | 6.64e-01 |
Tstage (T12 vs T3) | 0.51 (0.22–1.16) | 1.09e-01 | 0.51 (0.22–1.19) | 1.20e-01 | 0.48 (0.21–1.11) | 8.50e-02 |
Tstage (T4 vs T3) | 2.07 (1.46–2.92) | 3.92e-05 | 2.09 (1.48–2.96) | 3.03e-05 | 2.12 (1.50–3.00) | 2.36e-05 |
Nstage (N2 vs N1) | 2.18 (1.61–2.94) | 3.87e-07 | 2.23 (1.65–3.00) | 1.46e-07 | 2.25 (1.67–3.03) | 9.43e-08 |
LN | 0.73 (0.60–0.88) | 8.57e-04 | 0.73 (0.61–0.88) | 1.03e-03 | 0.73 (0.61–0.88) | 1.01e-03 |
Site (right vs left) | 1.70 (1.24–2.34) | 1.03e-03 | 1.61 (1.17–2.21) | 3.51e-03 | 1.60 (1.16–2.20) | 3.86e-03 |
MSI (MSS vs MSI-H) | 1.90 (0.99–3.65) | 5.22e-02 | 2.19 (1.14–4.21) | 1.80e-02 | 2.22 (1.15–4.27) | 1.69e-02 |
BRAF (mut vs wt) | 1.48 (0.82–2.65) | 1.93e-01 | 1.75 (0.98–3.11) | 5.65e-02 | 1.83 (1.03–3.26) | 3.86e-02 |
KRAS (mut vs wt) | 1.59 (1.14–2.21) | 5.73e-03 | 1.64 (1.18–2.28) | 3.32e-03 | 1.64 (1.18–2.28) | 3.54e-03 |
Note: the scores were standardized by IQR.